All of the counseling interventions for tobacco dependence demonstrated to be effective in this Guideline fall under these headings

Allergic (predominantly) asthma Allergic bronchitis NOS Allergic rhinitis with asthma Atopic asthma Extrinsic allergic asthma Hay fever with asthma Idiosyncratic asthma Intrinsic nonallergic asthma Nonallergic asthma Use additional code to identify: exposure to environmental tobacco smoke (Z77.22) exposure to tobacco smoke in the perinatal period (P96.81) history of tobacco use (Z87.891) occupational exposure to environmental tobacco smoke (Z57.31) tobacco dependence (F17.-) tobacco use (Z72.0) Excludes1: detergent asthma (J69.8) eosinophilic asthma (J82) lung diseases due to external agents (J60-J70) miner?s asthma (J60) wheezing NOS (R06.2) wood asthma (J67.8) Excludes2: asthma with chronic obstructive pulmonary disease chronic asthmatic (obstructive) bronchitis chronic obstructive asthma J45.2 Mild intermittent asthma J45.20 Mild intermittent asthma, uncomplicated Mild intermittent asthma NOS J45.21 Mild intermittent asthma with (acute) exacerbation J45.22 Mild intermittent asthma with status asthmaticus J45.3 Mild persistent asthma J45.30 Mild persistent asthma, uncomplicated Mild persistent asthma NOS J45.31 Mild persistent asthma with (acute) exacerbation J45.32 Mild persistent asthma with status asthmaticus J45.4 Moderate persistent J45.40 Moderate persistent, uncomplicated Moderate persistent asthma NOS J45.41 Moderate persistent with (acute) exacerbation J45.42 Moderate persistent with status asthmaticus J45.5 Severe persistent J45.50 Severe persistent, uncomplicated Severe persistent asthma NOS J45.51 Severe persistent with (acute) exacerbation J45.52 Severe persistent with status asthmaticus J45.9 Other and unspecified asthma J45.

Progress is also evident with tobacco use among middle and high school students
The first component (TAPS-1) is a four-item screen for tobacco, alcohol, illicit drugs, and non-medical use of prescription drugs
44 Bupropion is contraindicated in patients (1) with a seizure disorder, (2) with a history of anorexia or bulimia nervosa, (3) who are using another formulation of bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL), (4) who have used a monoamine oxidase inhibitor within the past 14 days, and (5) who are undergoing abrupt discontinuation of alcohol or sedatives (including benzodiazepines)